Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)

135.53
Delayed Data
As of Feb 23
 +1.68 / +1.26%
Today’s Change
13.09
Today|||52-Week Range
154.75
+47.65%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.9B

Company Description

Madrigal Pharmaceuticals, Inc. clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel compounds for the treatment of cardiovascular, metabolic and liver diseases. The company offers MGL-3196, an orally administered, small-molecule liver-directed ß-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Madrigal Pharmaceuticals was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Contact Information

Madrigal Pharmaceuticals, Inc.
500 Office Center Drive
Fort Washington Pennsylvania 19034
P:(610) 527-6790
Investor Relations:

Employees

Shareholders

Other institutional24.09%
Mutual fund holders12.54%
Individual stakeholders12.24%

Top Executives

Paul A. FriedmanChairman, President & Chief Executive Officer
Marc R. SchneebaumChief Financial Officer & Senior Vice President
Rebecca A. TaubDirector & Chief Medical Officer